Get the Stockscreener App
2.145
6.72%
0.135
Proqr Therapeutics N V stock is traded at $2.145, with a volume of 1.21M.
It is up +6.72% in the last 24 hours and down -9.87% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.01
Open:
$2
24h Volume:
1.21M
Relative Volume:
2.57
Market Cap:
$225.97M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.6626
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-9.11%
1M Performance:
-9.87%
6M Performance:
+18.51%
1Y Performance:
-38.18%
1-Day Range:
$1.96
$2.15
1-Week Range:
$1.91
$2.39
52-Week Range:
$1.07
$3.7065
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.145 | 211.74M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Is ProQR Therapeutics N.V. (0PQ) stock a good hedge against inflationWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is ProQR Therapeutics N.V. (0PQ) stock a buy during volatile marketsCPI Data & Weekly Top Performers Watchlists - Newser
Will ProQR Therapeutics N.V. (0PQ) stock enhance shareholder value2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
ProQR Therapeutics N.V. (PRQR) 5.47% in After-hours: Gains Ahead of Healthcare Conference - Stocks Telegraph
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - Setenews
Can ProQR Therapeutics N.V. (0PQ) stock surprise with quarterly results2025 Market Sentiment & Growth Focused Investment Plans - Newser
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
How ProQR Therapeutics N.V. (0PQ) stock valuation compares with sectorQuarterly Portfolio Report & Safe Capital Growth Tips - Newser
Why ProQR Therapeutics N.V. (0PQ) stock is a strong buy callMarket Risk Report & Smart Allocation Stock Tips - Newser
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leaders2025 Historical Comparison & Weekly Setup with High ROI Potential - Newser
Is ProQR Therapeutics N.V. stock attractive for hedge funds2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
ProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025 - Quiver Quantitative
ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewswire Inc.
How ProQR Therapeutics N.V. stock benefits from global expansionQuarterly Investment Review & Comprehensive Market Scan Reports - BỘ NỘI VỤ
Is ProQR Therapeutics NV 0PQ a good long term investmentFundamental Strength Indicators & Low Entry Investment Ideas - earlytimes.in
Taking on analysts’ expectations and winning: ProQR Therapeutics N.V (PRQR) - Setenews
Activity Recap: Why ProQR Therapeutics N.V. stock is a value investor pickJuly 2025 Volume & Capital Protection Trade Alerts - moha.gov.vn
ProQR Therapeutics NV Stock Analysis and ForecastVWAP Trading Strategies & Market Trend Real-Time Reports - earlytimes.in
Whale Trades: Why ProQR Therapeutics N.V. stock is considered a top pick - BỘ NỘI VỤ
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is ProQR Therapeutics N.V. stock a safe haven assetWeekly Profit Report & Free Community Consensus Stock Picks - BỘ NỘI VỤ
ProQR Therapeutics N.V. (0PQ.F) analyst ratings, estimates and forecasts - Yahoo Finance Singapore
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk - simplywall.st
Can ProQR Therapeutics N.V. (0PQ) stock sustain breakout momentum - newser.com
Is ProQR Therapeutics N.V. stock cheap compared to fundamentals2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - newser.com
Why analysts raise outlook for ProQR Therapeutics N.V. (0PQ) stockGap Down & High Yield Equity Trading Tips - newser.com
Is ProQR Therapeutics N.V. (0PQ) stock worth buying before Fed action2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Can ProQR Therapeutics N.V. (0PQ) stock sustain free cash flowPortfolio Return Report & Detailed Earnings Play Alerts - newser.com
Will ProQR Therapeutics N.V. (0PQ) stock boost dividends furtherJuly 2025 Closing Moves & Short-Term Trading Alerts - newser.com
Why analysts recommend ProQR Therapeutics N.V. (0PQ) stockWeekly Trade Review & Smart Investment Allocation Tips - newser.com
Published on: 2025-11-19 18:47:14 - newser.com
Is ProQR Therapeutics N.V. (0PQ) stock a buy before new product rollout2025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Is ProQR Therapeutics N.V. stock attractive for income investorsJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Pattern recognition hints at ProQR Therapeutics N.V. upsideEarnings Beat & Weekly Watchlist of Top Performers - newser.com
Published on: 2025-11-19 13:24:00 - newser.com
Will ProQR Therapeutics N.V. stock gain from government policiesJuly 2025 Momentum & Daily Chart Pattern Signals - newser.com
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):